Passage Bio, INC Schedule 13D activist filings

Lynx1 Capital Management LP and Weston Nichols have disclosed a beneficial ownership of 21.0% of Passage BIO, Inc. common stock, totaling 673,759 shares, following recent transactions and in anticipation of a merger with Remix Therapeutics.

OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC have filed an exit Schedule 13D, reporting a decrease in their beneficial ownership of Passage BIO, Inc. common stock to below 5%.

OrbiMed Advisors and OrbiMed Capital GP VII have reduced their beneficial ownership in Passage Bio, Inc. to 7.82% after a series of share sales and a 1-for-20 reverse stock split.

OrbiMed Advisors and OrbiMed Capital GP VII have significantly reduced their beneficial ownership in Passage BIO, Inc. to 9.5% through a series of share sales in late June and early July 2025.

OrbiMed Advisors and OrbiMed Capital GP VII LLC have filed an Amendment No. 6 to their Schedule 13D, reporting a decrease in their beneficial ownership of Passage BIO, Inc. common stock to 10.7% following recent share sales.